Q3 2025 EPS Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO) Boosted by Zacks Research

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research raised their Q3 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a note issued to investors on Monday, August 26th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $3.06 for the quarter, up from their prior forecast of $3.04. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.80 per share.

BIO has been the topic of a number of other research reports. UBS Group cut their target price on shares of Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Royal Bank of Canada restated an “outperform” rating and set a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research report on Tuesday. They issued an “equal weight” rating and a $340.00 target price on the stock. Jefferies Financial Group restated a “hold” rating and set a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research report on Monday, June 3rd. Finally, Citigroup boosted their target price on shares of Bio-Rad Laboratories from $300.00 to $350.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $358.20.

Bio-Rad Laboratories Trading Up 1.5 %

NYSE BIO opened at $333.71 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.89 and a current ratio of 6.57. Bio-Rad Laboratories has a one year low of $261.59 and a one year high of $406.44. The company has a 50-day simple moving average of $306.90 and a 200-day simple moving average of $308.08. The firm has a market capitalization of $9.52 billion, a PE ratio of -32.21 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.56% and a negative net margin of 51.73%. The business had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. During the same period in the prior year, the company posted $3.00 EPS. The business’s revenue was down 6.3% compared to the same quarter last year.

Insiders Place Their Bets

In other news, EVP Michael Crowley sold 369 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $281.91, for a total value of $104,024.79. Following the completion of the transaction, the executive vice president now directly owns 6,573 shares in the company, valued at $1,852,994.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 17.06% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Van ECK Associates Corp bought a new stake in shares of Bio-Rad Laboratories in the 2nd quarter worth approximately $180,040,000. First Eagle Investment Management LLC raised its position in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after purchasing an additional 634,311 shares during the period. Norges Bank purchased a new position in Bio-Rad Laboratories in the 4th quarter worth about $73,142,000. Dimensional Fund Advisors LP raised its holdings in Bio-Rad Laboratories by 64.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock worth $135,081,000 after buying an additional 193,700 shares during the period. Finally, Parsifal Capital Management LP acquired a new stake in Bio-Rad Laboratories during the 4th quarter worth about $61,866,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.